Pursue Wealth Partners LLC Takes Position in Ascendis Pharma A/S (NASDAQ:ASND)

Pursue Wealth Partners LLC purchased a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,451 shares of the biotechnology company's stock, valued at approximately $226,000.

Several other large investors have also recently added to or reduced their stakes in ASND. Harbor Capital Advisors Inc. increased its position in shares of Ascendis Pharma A/S by 1.3% during the first quarter. Harbor Capital Advisors Inc. now owns 85,960 shares of the biotechnology company's stock valued at $13,398,000 after purchasing an additional 1,087 shares during the period. Toth Financial Advisory Corp acquired a new stake in Ascendis Pharma A/S during the first quarter worth $832,000. GAMMA Investing LLC increased its holdings in Ascendis Pharma A/S by 15,593.0% in the 1st quarter. GAMMA Investing LLC now owns 91,490 shares of the biotechnology company's stock valued at $142,600,000 after buying an additional 90,907 shares during the period. GF Fund Management CO. LTD. bought a new stake in Ascendis Pharma A/S in the 4th quarter valued at $174,000. Finally, Woodline Partners LP raised its stake in shares of Ascendis Pharma A/S by 35.2% in the 4th quarter. Woodline Partners LP now owns 317,642 shares of the biotechnology company's stock valued at $43,730,000 after buying an additional 82,624 shares in the last quarter.

Ascendis Pharma A/S Trading Up 1.9%

Shares of Ascendis Pharma A/S stock traded up $3.32 during midday trading on Tuesday, reaching $179.10. The company had a trading volume of 377,009 shares, compared to its average volume of 496,069. The stock has a fifty day simple moving average of $165.82 and a 200 day simple moving average of $150.07. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $183.00. The company has a market capitalization of $10.95 billion, a price-to-earnings ratio of -28.52 and a beta of 0.37.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The firm had revenue of $123.97 million during the quarter, compared to the consensus estimate of $98.56 million. Sell-side analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on ASND shares. JPMorgan Chase & Co. upped their target price on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the company an "overweight" rating in a research note on Friday, May 2nd. Evercore ISI lifted their price objective on Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Cantor Fitzgerald reissued an "overweight" rating and issued a $200.00 target price on shares of Ascendis Pharma A/S in a report on Monday, May 12th. Wedbush boosted their price target on Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Finally, Bank of America increased their price objective on Ascendis Pharma A/S from $201.00 to $216.00 and gave the stock a "buy" rating in a research note on Monday, June 9th. One research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, Ascendis Pharma A/S has a consensus rating of "Moderate Buy" and an average target price of $220.67.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.